DNMT1 and T-cell non-Hodgkin lymphoma: For example, T-cell lymphomas are driven by some epigenetic defects [39], and sensitivity to epigenetic therapies such as histone deacetylase (HDAC) inhibitors (e.g., romidepsin) or DNMT inhibitors [38] has been noted.